DAY 1

DAY 2

Speakers

Speakers

PROGRAM

2 DAYS OF HIGH LEVEL CONFERENCES

The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.

CAR-T CELLS (I) - (II)

Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease of patients suffering from Refractory/ Resistant Hematologic malignancies. This success has now lead the FDA and EMA to approve rapidly these innovative cellular drugs.

Based on these unexpected and impressive results, the world of cellular immunotherapy offers new perspectives. The two sessions dedicated to CAR expressing T or NK [Dr Mattias Carlsen] autologous or allogeneic cells [Dr Laurent Poirot] will cover a range of topics from research [Dr Emmanuel Donnadieu (imaging), Dr Suman Mitra (cytokines’ use improvement), Dr Marco Ruella (understanding escape)] to the clinic [Dr Jordan Gauthier, Pr André Baruchel] through drug production [Dr Isabelle Rivière, Dr Georg Rauser].

 

It will also give another view of the remarkable potential of this approach in solid tumors [Pr Stephan Depil]. It will explain how European Bone Marrow Transplantation registry may help in better understanding Immune Effector Cells derived therapeutics [Pr Christian Chabannon].

Mix and exchanges of people from different backgrounds (academic, scientists, pharmacists, clinicians, private companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.

IPS & MSCS

This session will gather experts in the development of IPS and MSCs cell-based therapies to the clinic. IPs will be discussed as source of hematopoietic cells [Nico Lachmann] or tissues [John de Vos] and MCSs in the context of auto or allo-therapies [Jens Kastrup] or in rheumatoid diseases [Christian Jorgensen].

Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.

REGULATORY & BIO-PROD PLATFORMS

This session will give us an overview of the regulatory guidelines defined for ATMP and border-line products [Nicolas Ferry], a review of the last months of work of the ANSM gate dedicated to innovative products [Marc Martin] as well as the European view of ATMP deployment in hematological malignancies [Christian Chabannon]. Also, difficulties and success in the production of such products will be tell with concrete examples by people facing production and regulatory constraints [Hélène Negre-Trebeden; Anne Fialaire-Legendre; Fabienne Pouthier].

Thursday, October 14th

9:00-09:30 : Welcome and Keynote address (Kursaal conf room)

Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR

Welcome words from the urban community’s President
Welcome words from the Region’s President
Welcome words from the Pôle des Microtechniques’ President
Welcome words from the National French Blood Center’s President

 

9:30-12:30 : CAR-T Cells (I) (Kursaal conf room)

Chairmen: Christophe Ferrand and Marina Deschamps, RIGHT institute, Besançon, FR

9:30 : CAR-T cells production

Isabelle Rivière, Memorial Sloan Kettering, NYC, USA

10:00 : The path towards point-of-care manufacturing of gene-engineered T cells

Georg Rauser, Miltenyi Biomedicine, DE

10:30 : BREAK

11:00 : Monitoring CAR-T cell efficacy in human tumor samples

Emmanuel Donnadieu, INSERM, Institut Cochin, Paris, FR

11:30 : CAR-T cells in solid tumors: challenges and perspectives

Stephane Depil, Centre Léon Bérard, Lyon, FR

12:00 : Bringing allogeneic CAR-T therapies to the clinic

Laurent Poirot, Cellectis, Paris, FR

12:30-14:00 : Lunch (Kursaal Ballroom or BioInnovation)

14:00-16:00 : Visit of BioInnovation

14:00-16:00 : B2B Meetings

16:00-16h30 : BREAK

16:30-19:30 : IPS & MSCs (Kursaal conf room)

Chairmen: Marie José Stasia, Grenoble Alpes University, Grenoble, FR

and Sylvain Perruche, RIGHT Institute, Besançon, FR

16:30 : Update on MSC based therapy in rheumatic diseases

Christian Jorgensen, INSERM U1183, IRMB, Montpellier, FR

17:00 : The experience road from autologous to allogeneic clinical cell products

Jens Kastrup, Rigshospitalet, DK

17:30 : Driving iPS-derived bronchial cells into the clinic : mind the gap

John de Vos, INSERM U1183, CHU Montpellier, FR

18:00 : BREAK

18:30 : iPSC-derived hematopoietic cells and cell-based therapies

Nico Lachmann, Hannover Medical School, Hannover, DE

19:00-19:30 : Induced pluripotent stem cells for cancer studies and therapies 

Annelise Bennaceur, Center for IPS Therapies CITHERA, INSERM U935/UA09 ESTeam, University Paris Saclay, FR

20:00-23:30 : Evening reception (Kursaal Ballroom)

 

Friday, October 15th

9:00-11:00 : Regulatory & Clinical transfer of innovative therapies (Kursaal Conf room)

Chairmen: Mathieu Guerriaud, CREDIMI, Dijon, FR

and Pierre Tiberghien, EFS, Paris, FR

09:00 : The Regulation of ATMP + Difficulties and succes for clinical transfer

Nicolas Ferry, Paris, FR

Hélène Negre-Trebeden, Paris, FR  ex-Dana-Farber Cancer Institute

10:00 : 8-month review of the innovation portal

Marc Martin, ANSM, FR

10:30 : PRESENTATION OF THE EFS PHARMACEUTICAL ESTABLISHMENT AND LOCAL SPECIFICITIES

Anne Fialaire-Legendre, EFS, FR  &  Fabienne Pouthier, EFS BFC, FR

11:00 : The use of the EBMT registry for follow-up of patients treated with Immune Effector Cells derived therapeutics

Christian Chabannon, Institut Paoli-Calmettes, Marseille, FR

11:30 : BREAK

11:30-12:30:  B2B meetings (Kursaal Ballroom)

12:30-14:00 : Lunch (Kursaal Ballroom)

14:00-17:00 CAR T-Cells (II) (Kursaal Conf room)

Chairmen: Eric Deconinck, RIGHT institute, Besançon, FR

and Suman Mitra, INSERM, Lille, FR

14:00 : Understanding resistance to CAR-T cells to develop next-generation immunotherapies

Marco Ruella, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA

14:30 : Tuning cytokine-induced signaling pathways to refine current cell therapy protocols

Suman Mitra, INSERM, Lille, FR

15:30 : BREAK

16:00 : OVERVIEW OF TOXICITIES AFTER CAR T CELL THERAPY

Jordan Gauthier, Fred Hutchinson Cancer  Research Center , University of Washington, Seattle, WA, USA

16:30-17:00  : Chemical and genetic strategies to improve CRISPR mediated knock-in

Marcello Maresca, AstraZeneca, Sweden, SW

17:15-23:30 Evening cocktail (Besançon)

Join us and meet our speakers

André Baruchel – Hôpital Robert-Debré (Paris, FR), Annelise Bennaceur, INSERM U935 ESTeam, University Paris Saclay (Paris, FR), Christian Chabannon – Institut Paoli-Calmettes (Marseille, FR), Bruno Dalle, Yposkesi (Corbeille-Essonnes, FR), Stéphane Depil – Centre Léon Bérard (Lyon, FR), John de Vos – INSERM U1183, IRMB (Montpellier, FR), Emmanuel Donnadieu – INSERM, Institut Cochin (Paris, FR), Nicolas Ferry (Paris, FR), Jordan Gauthier – Fred Hutch CR (Seattle, USA), Christian Jorgensen – INSERM U1183, IRMB (Montpellier, FR), Jens Kastrup – Rigshospitalet (DK), Nico Lachmann – Hannover Medical School (Hannover, DE), Marcello Maresca, Astrazeneca (Södertälje, SW), Suman Mitra – INSERM (Lille, FR), Constance Perrot, EASE (Illkirch, FR), Laurent Poirot – Cellectis (Paris, FR), Georg Rauser, Miltenyi Biomedicine (Bergisch Gladbach, DE), Isabelle Rivière – Memorial Sloan Kettering (New-York City, USA), Marco Ruella – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA), Pierre Tiberghien – EFS (Paris, FR)…

Speakers